Navigation Links
Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
Date:11/27/2011

hilia A is caused by a factor VIII deficiency and the congenital form occurs in ~1 out of every 5,000 male births.  Hemophilia B is caused by factor IX deficiency and occurs in ~1 out of every 30,000 male births.  Approximately 60% of persons with hemophilia have a severe condition, which results in frequent spontaneous bleeding episodes, in addition to serious bleeding after injuries.  The annual market for hemophilia treatments is estimated at $8 billion worldwide.

Approximately one-third of individuals with hemophilia A develop an immune reaction (inhibitors) to human FVIII, and can no longer respond to replacement treatment with the coagulation factor.  Current therapies, specifically human factor VIIa (NovoSeven®) and FEIBA, work by bypassing the natural hemostatic pathway.

About OBI-1OBI-1, a recombinant form of porcine FVIII which may possess low cross reactivity to antihuman FVIII antibodies, is a replacement therapy, facilitating the intrinsic hemostatic pathway.  This should allow clinicians to correlate activity and efficacy with FVIII levels, a surrogate for efficacy in hemophilia, and therefore guide dosing to better monitor and predict treatment outcomes.  OBI-1 presents a unique and alternative approach to address the needs of individuals who have developed inhibitors to FVIII and is highly desired by the medical community.

For more information about enrolling in one of Inspiration's clinical trials, please visit www.hemophiliaregistry.com or call 1-800-361-3227.  For more information on the ongoing clinical studies, please visit http://www.clinicaltrials.gov.

About Inspiration BiopharmaceuticalsInspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care, including prophylactic therapy, and to improve t
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Inspiration for My Sisters Keeper Speaks Out
4. National Expressions of Courage Art Contest Unveils Stories of Inspiration
5. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
6. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
7. Siemens MAMMOMAT Inspiration Digital Mammography Commercially Available in U.S.
8. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
9. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
10. Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress
11. Heskas 2011 "Inspiration in Action" Contest Begins: Support the Veterinary Profession and Help Animals in Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , April 28, 2015  Spark Therapeutics, ... Inc. announced today that they have entered into ... rights to license Clearside,s microinjector technology to deliver ... Under the agreement, the companies will explore the ... viral vectors to the choroid and the retina ...
(Date:4/28/2015)... 2015  Ascendis Pharma A/S (Nasdaq: ... that applies its TransCon technology to address ... its Phase 1 single ascending dose study ... plasma treprostinil levels in-line with expectations.  However, ... the criteria defined in the target product ...
(Date:4/28/2015)... , April 28, 2015  Nevro Corp. (NYSE: ... developed and commercialized an innovative, evidence-based neuromodulation platform for ... will release financial results for the first quarter of ... Company management will host a conference call beginning at ... Monday, May 11, 2015. Individuals interested ...
Breaking Medicine Technology:Spark Therapeutics and Clearside Biomedical Announce Exclusive Option to License Technology for Potentially Differentiated Delivery of Gene Therapy to the Eye 2Spark Therapeutics and Clearside Biomedical Announce Exclusive Option to License Technology for Potentially Differentiated Delivery of Gene Therapy to the Eye 3Spark Therapeutics and Clearside Biomedical Announce Exclusive Option to License Technology for Potentially Differentiated Delivery of Gene Therapy to the Eye 4Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil 2Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil 3Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil 4
... IsZo Capital Management LP, one of the largest minority shareholders ... ), announced today that it delivered the following letter to ... immediately from the agenda for the upcoming annual shareholders, meeting ... 2011 Board of Directors of Taro Pharmaceutical Industries ...
...  GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm ... Immunodeficiency Virus (HIV) infections, announced that the first patient ... for the Company,s HIV/AIDS therapeutic vaccine.  This is the ... of persons who are HIV infected. The ...
Cached Medicine Technology:IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 2IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 3IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 4IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 5GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine 2GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine 3
(Date:4/28/2015)... Aurora, IL (PRWEB) April 28, 2015 ... and subsidiary of Briggs and Stratton, raised nearly $12,000 ... campaign that began in October 2014. MWE announced the ... to raise funds and awareness for wounded service members ... national nonprofit dedicated to restoring a sense of self, ...
(Date:4/28/2015)... VA (PRWEB) April 28, 2015 Sentara ... to securely share electronic patient health information across the ... and outpatient facilities in Hampton Roads and northern Virginia ... early adopters of a nationwide effort to improve care ... Roads and northern Virginia have one of the largest ...
(Date:4/28/2015)... Allied Anesthesia physicians are embracing the ... and is swiftly gaining ground across the country. , ... the experience more enjoyable and memorable for the mother ... process between mother and baby. , “We’re the hand ... Allied. , Maya and other Allied anesthesiologists have been ...
(Date:4/28/2015)... 2015 HomeTown Health, LLC held its ... at the Riverside Marriott in Savannah, Georgia with leading ... expertise and best practices required to survive the effects ... this conference was outstanding, and offers unparalleled value in ... sensitive and pressing needs of our hospitals.” said HomeTown ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 The Lymphoma ... devoted exclusively to funding innovative lymphoma research and serving ... programs, outreach initiatives and patient services – will once ... in Scarsdale, New York to host its Annual Golf ... will take place on May 18, 2015. , ...
Breaking Medicine News(10 mins):Health News:Midwest Engine Exceeds Donation Goal for the Second Year to Hope For The Warriors 2Health News:Sentara Healthcare Begins Sharing Electronic Patient Data with Department of Defense 2Health News:Allied Anesthesia Physicians Promote Gentle C-sections 2Health News:HomeTown Health Convenes Meeting of Leading Rural Health Experts in Savannah to Share Solutions for Survival at 15th Annual Spring Conference 2Health News:HomeTown Health Convenes Meeting of Leading Rural Health Experts in Savannah to Share Solutions for Survival at 15th Annual Spring Conference 3Health News:Lymphoma Research Foundation Returns to Prestigious Quaker Ridge Golf Club in Scarsdale, NY for Annual Golf Invitational 2
... 2, 2012 Combination drug therapy may be needed to ... by the Translational Genomics Research Institute (TGen) and Van Andel ... JAK2 Independent of Key Oncogenic Driver Mutation in Non-Small Cell ... the Public Library of Science (PLoS) ONE . ...
... Feb. 2 (HealthDay News) -- The sale of pet turtles ... the small reptiles are still available and continue to infect ... of the health danger, pet turtles are inappropriate pets in ... pregnant women, seniors and those with weak immune systems, according ...
... the most distinctive signs of the development of Alzheimer,s ... protein that neuroscientists call tau. In normal brains, tau ... In the cells of Alzheimer,s brains, by contrast, tau ... These tangles are considered a hallmark of the disease, ...
... Different kinds of lung cancer behave in different ways, ... University of Colorado Cancer Center study published in ... Society, different subgroups of non-small cell lung cancer (NSCLC) ... The study looked at 209 patients diagnosed with ...
... reason the prognosis for metastatic colon cancer has gone from ... Unfortunately, the drug can also carry with it debilitating neurological ... and needles in fingers and toes and can leave patients ... don,t receive the necessary dose to try to keep their ...
... -- A warning to certain types as those Super Bowl ... are more likely to eat too much in social situations, ... pressure to eat when they believe that their eating will ... Exline, a psychologist at Case Western Reserve University, said in ...
Cached Medicine News:Health News:Combination drug therapy urged to battle lung cancer 2Health News:Pet Turtles Carry Salmonella Dangers, CDC Warns 2Health News:Untangling the mysteries of Alzheimer's 2Health News:New research confirms need for lung cancer testing 2Health News:Balancing oxaliplatin dose with neurological side effects in metastatic colon cancer 2Health News:'People Pleasers' More Prone to Overeating: Study 2
... 220XiIII quickly prints labels up ... 10 ips. It is ideal ... as printing chemical drum labels, ... industry labels, banner-sized labels and ...
... Verification System, is used by hospitals ... the specific unit(s) of blood that ... It has the additional benefit of ... institution's policy and procedure for blood ...
... This system helps ensure a safe care environment ... down to the unit dose level. The automated ... track the location and handling of all items, ... eye preparations and more. This saves valuable time ...
... ensures your patients are receiving the proper ... uses the AutoPPI™ barcoded wristband to positively ... transfusion. SafeTx checks that the correct blood ... bedside paperwork and associated transcription errors. In ...
Medicine Products: